Cancer Monoclonal Antibodies Market

Cancer Monoclonal Antibodies Market Size (2022 to 2027)

The global cancer monoclonal antibodies market is forecasted to be worth USD 78.55 billion by 2027 from USD 45.97 billion in 2022, registering a CAGR of 11.31% between 2022 to 2027.

A few of the key insights from this report:

• Based on application, the blood cancer segment dominated the market and accounted for 24.8% of the global market share in 2021.
• Based on region, North America captured 40.2% of the global market share in 2021.
• The European region is predicted to be worth USD 26.25 billion by 2027.
• The Asia-Pacific region is anticipated to grow at a CAGR of 13% from 2022 to 2027.

Cancer is a severe disease-causing million of deaths worldwide every year. Cancer starts from a single cell and genetically transforms a normal cell into a tumor cell and gradually spreads to other cells. With the dramatic increase in the number of people affected by cancer, many pharmaceutical players invested in monoclonal antibodies. However, while the drugs treat cancer, chemotherapy agents have adverse side effects on normal and cancerous cells. Therefore, it prompted the increased usage of monoclonal antibodies to treat cancer.

Monoclonal Antibodies (mAbs) are mono-specific antibody bodies comprising identical immune cell clones of a single parent cell and directed to specific cellular targets. Thus, monoclonal antibodies are highly customizable due to their nature and can play a crucial role in eliminating cancerous cells while sparing the normal cells during the cancer treatment. Monoclonal antibodies are proven more effective than chemotherapies and drugs for cancer treatment. Monoclonal Antibodies could offer less toxic and more efficient therapeutic alternatives to patients emerging in recent years. Monoclonal Antibodies are used to treat a wide array of autoimmune, inflammatory, and especially cancer.

MARKET DRIVERS:

YOY rise in the prevalence of cancer, growing investments for R&D of genomic studies, and increasing progress and preference towards the specificity of monoclonal antibodies to attack cancer are majorly propelling the cancer monoclonal antibodies market growth.

According to the WHO, cancer is the second leading cause of death globally, registering an estimated 9.9 million deaths, or 1 in 6 deaths, in 2019. Cancer associated with prostate, colorectal & liver is the most common cancer in men, while cancer associated with colorectal, lung, cervical & thyroid cancer is most commonly affected by women. Therefore, the increase in data should inform any national cancer policy, leading to a rise in the percentage of people choosing cancer treatment. In the health sector, cancer is one of the biggest concerns. Therefore, increasing monoclonal antibodies for cancer treatment is boosting this market.

The dramatic increase in cancer patients has led many pharmaceutical players to invest in the cancer monoclonal antibodies market. Increasing investment in R&D of genomic studies, technological advancements in genetic sequencing and target gene selection, and a specificity of monoclonal antibodies to target only the cancer cells with no side effects are some of the market's driving forces. The increased prevalence of cancer is the key driver of the monoclonal antibodies market. With health products in the pipeline, it is expected to grow lucratively in the next five years.

Due to the growing demand, there is a rapid increase in R&D activities of genomic studies. This has led to a rapid rise in the cancer monoclonal antibodies market. In addition, it is also believed that the increase in the prevalence of breast cancer promotes the development of the global cancer monoclonal antibodies market.

MARKET RESTRAINTS:

However, following regulatory guidelines for cancer-related monoclonal antibodies is a very rigorous process in most parts of the world. The guidelines provide a complete description of the manufacturing processes, including quality, good manufacturing practices, process validation, the potential for degradation, and the need for stability studies. Therefore, globally, there is a strict regulatory scenario like the US FDA, European Medicines Agency (EMA), and Korean FDA. Cancer antibodies also face similar restrictions in gaining approval for monoclonal antibodies in the market. As this is a long process, it is considered one of the main hurdles for this market.

The growth of the cancer monoclonal antibodies market is a long period of research and development before clinical trials, the increase in mAbs failures in clinical trials, and the high cost of the products defying the market's growth rate.

Impact of COVID-19 on the global cancer monoclonal antibodies market:

The World Health Organization (WHO) declared the COVID-19 pandemic a public health emergency affecting millions of people and spreading to every corner of the world. The pandemic has affected all sectors, including the medical field. During the COVID-19 outrage, the pharma industry was more bothered about developing the COVID-19 vaccine. As a result, cancer monoclonal antibodies' research and development activities have dropped, even though the demand for cancer monoclonal antibodies is stable and high before the pandemic. During the pandemic lockdown, there has been a slight decline in cancer monoclonal antibodies. However, the market position is forecasted to fall in its place by the end of 2021.

REPORT COVERAGE:

This research report on the global cancer monoclonal antibodies market has been segmented and sub-segmented based on application, type, conjugate cancer therapies, and region.

Cancer Monoclonal Antibodies Market - By Application:

• Liver
• Breast
• Brain
• Blood
• Hodgkins and Non-Hodgkins lymphoma           
• Colorectal
• Leukemia
• Others

Based on the application, the blood cancer segment led the cancer monoclonal antibodies market in 2021 and is expected to perform well during the forecast period.

On the other hand, the breast cancer segment is anticipated to showcase the highest CAGR in the global cancer monoclonal antibodies market during the forecast period. Growing exposure to harmful radiation, insufficient physical exercise, and expanding unhealthy lifestyles mobilize the market growth. In addition, large companies' growth in investments, increasing government initiatives, and rising female population push the market forward.

Cancer Monoclonal Antibodies Market - By Type:

• Murine Antibodies
• Chimeric and Humanised Antibodies
• Fully Humanized Antibodies

Based on type, the murine antibodies account for the lion's share in the cancer monoclonal antibodies type during the forecast period. The murine antibodies play a significant role in advancing present-day antibody production procedures and developing the potential usage of immunoglobins for various applications propelling the market growth. 

The fully humanized antibodies segment is the quickest growing, with a CAGR rate during the forecasting framework. In addition, the integration of advanced technologies like yeast or phase display showcases their market growth. 

Cancer Monoclonal Antibodies Market - By Conjugate Cancer Therapies:

• Immunoliposome
• Radioimmunotherapy
• ADEPT
• Immunocytokines
• Others

The radioimmunotherapy segment is forecasted to dominate the cancer monoclonal antibodies market during the forecast period due to the increasing number of cancer patients with the growing number of hospitals and diagnostic centers.

Cancer Monoclonal Antibodies Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

The North American cancer monoclonal antibodies market dominated the global market and is estimated to be worth USD 17.53 billion by 2027 owing to the well-established healthcare infrastructure, increased government investments for infection control and management, and the rising commonness of lifestyle-related diseases. In addition, the North American region shows promising growth due to its rise in cancer research and technological developments. In this region, during the forecast period, the U.S. cancer monoclonal antibodies market is forecasted to grow at a notable growth rate. On the other hand, the Canadian market is expected to showcase a healthy CAGR.

The European cancer monoclonal antibodies market is anticipated to show a prominent growth rate of 10.9% during the forecast period owing to increased everyday awareness of autoimmune diseases, the cancer population, and rising funding in research and development in the monoclonal antibodies market. In Europe, U.K. and Germany are expected to register significant market share. 

The cancer monoclonal antibodies market in the APAC was worth USD 6.71 billion in 2022. The Asia-Pacific market is regarded to increase significantly due to increased spending capacity and the growing knowledge among patients.

The Latin America cancer monoclonal antibodies market is predicted to have a moderate growth rate during the forecast period.

The cancer monoclonal antibodies market in the Middle East and Africa is expected to register a sluggish CAGR during the forecast period.

KEY MARKET PLAYERS:

The highly customizable nature of monoclonal antibodies attracts various organizations, research institutes, and multinational companies to use them to cure cancer. The major players in the Cancer Monoclonal Antibodies Market are Amgen, Genmab, GlaxoSmithKline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics & Spectrum Pharmaceuticals.

RECENT MARKET DEVELOPMENTS:

• In 2020, Merck launched the biosimilar trastuzumab, a monoclonal antibody used to treat certain breast cancers.
• In 2018, Pfizer Inc. declared the US FDA approval of ZIRABEV (bevacizumab-bvzr). It is a biosimilar to Avastin (bevacizumab), which is indicated to treat five types of cancer, including locally advanced, relapsed or metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer, non-metastatic renal cell carcinoma resectable (CCR), recurrent glioblastoma; and persistent, recurrent or metastatic cervical cancer. This is the second oncology monoclonal antibody biosimilar to gain FDA approval after TRAZIMERA (trastuzumab-qyyp) in March 2019. This new biosimilar may help increase access to impactful therapies, thereby accelerating competition in the market. As a result, it can potentially reduce costs and help meet the various demands of cancer patients.
• In 2016, ImmunoGen Inc agreed with Merck to evaluate mirvetuximab soravtansine to treat patients with FRα-positive ovarian cancer.